Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116026 | 0.82 | PTGDR2 (0.67) | PTGDR2MEN1KMT2A | |
| SCHEMBL4116024 | 0.82 | PTGDR2 (0.67) | PTGDR2MEN1KMT2A | |
| SCHEMBL4124530 | 0.80 | PTGDR2 (0.55) | P2RY1PTGDR2MEN1KMT2A | |
| SCHEMBL6967683 | 0.76 | P2RY1 (0.56) | P2RY1ABCB1ALDH1A1 | |
| SCHEMBL4123966 | 0.73 | PTGDR2 (0.79) | PTGDR2MEN1KMT2A | |
| SCHEMBL4128548 | 0.73 | PTGDR2 (0.76) | PTGDR2MEN1KMT2A | |
| SCHEMBL4124396 | 0.70 | PTGDR2 (0.52) | PTGDR2MEN1KMT2A | |
| SCHEMBL4124398 | 0.70 | PTGDR2 (0.52) | PTGDR2MEN1KMT2A | |
| SCHEMBL4123926 | 0.70 | PTGDR2 (0.82) | PTGDR2MEN1KMT2A | |
| SCHEMBL4129447 | 0.69 | PTGDR2 (0.76) | PTGDR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | P2RY1 387/4885PTGDR2 1/4885ABCB1 2029/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | P2RY1 245/4885PTGDR2 1/4885ABCB1 1959/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | P2RY1 387/4885PTGDR2 1/4885ABCB1 2029/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | P2RY1 357/4885PTGDR2 1/4885ABCB1 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.